Featured Research

from universities, journals, and other organizations

Scientists View 'Dark Side' Of The Body

Date:
September 3, 2004
Source:
University Of Southern California
Summary:
Over the last decade, USC chemist Nicos A. Petasis has worked as part of a multidisciplinary team studying the natural course of inflammation and what goes wrong in disease. Led by Harvard biologist Charles N. Serhan, the team’s research has altered fundamental ideas about the inflammatory response and revealed the role of biological molecules called lipoxins in regulating the process.

Even the tiniest paper cut kicks the immune system into action. Infection-fighting white blood cells, called neutrophils, rush to the site of injury and initiate inflammation.

Related Articles


Calling for back up, the neutrophils quickly recruit more of their kind to the scene, and commence to kill any bacteria they find. The skirmishes and casualties cause the skin around the cut to swell and redden until, victory in sight, the first wave of inflammation subsides. As the neutrophils retreat, the healing can begin.

Yet these defensive forces have a dark side as well. Unchecked, raging inflammation can damage the very tissues the immune system is designed to protect. In fact, researchers have linked out-of-control inflammation to an ever-growing list of diseases, from clogged arteries and heart attacks to arthritis and cancer.

Over the last decade, USC chemist Nicos A. Petasis has worked as part of a multidisciplinary team studying the natural course of inflammation and what goes wrong in disease.

Led by Harvard biologist Charles N. Serhan, the team’s research has altered fundamental ideas about the inflammatory response and revealed the role of biological molecules called lipoxins in regulating the process.

As part of the effort, Petasis and his group have synthesized a number of powerful chemical compounds that mimic lipoxin’s anti-inflammatory, pro-healing activity.

The compounds, called lipoxin analogs, are now being eyed as candidates for drug development, having shown great promise in quelling disease-associated inflammation in animal studies of dermatitis, asthma, kidney disease and now gum disease and cystic fibrosis.

In his efforts to invent new materials and pharmaceuticals, Petasis, holder of the Harold and Lillian Moulton Chair in Chemistry in the USC College of Letters, Arts and Sciences and member of USC’s Loker Hydrocarbon Research Institute, looks to nature for inspiration.

Finding ways to improve on nature’s designs was at the heart of the challenge when Serhan and Petasis began collaborating in 1993.

The pair had worked together earlier as members of the teams of their mentors – Nobel-prize winning Swedish biologist Bengt Samuelsson and preeminent synthetic chemist K. C. Nicolaou, respectively – who had joined forces to study other aspects of inflammation.

Although Serhan discovered the lipoxins with Samuelsson in the 1980s, he wasn’t able to fully determine their function for years. A breakthrough came when he showed why lipoxins had resisted study. They circulated only a few minutes before enzymes broke them down.

“When Serhan discovered that, we started work synthesizing longer-lasting lipoxin-like molecules,” said Petasis, “My task was to protect the molecules from the enzymes without altering their biological activity.”

It was a tricky prospect.

With a rough design in mind, Petasis began his hands-on work. He would send his most promising molecules to Serhan to test for activity and metabolic stability.

Doing this, Petasis created a few dozen promising analogs. Adding a fluorine atom to his best prospect, he came up with what he was after – a potent lipoxin analog that lasts for hours.

Using the lipoxin analogs as tools, the team went on to reveal that lipoxins worked as the immune system’s “traffic cops” to halt inflammation, among other key activities. Anti-inflammatory lipoxins – produced by neutrophils in the same biochemical cascade that initiates inflammation – signal other cells to retreat from an inflamed site and to begin the healing process.

The team’s research also led to a clearer understanding of how aspirin dampens inflammation. Scientists had known that aspirin works by blocking pro-inflammatory molecules, but Serhan was the first to show that aspirin also triggers the formation of a distinct, longer-lived form of lipoxin, which was first synthesized by Petasis.

As part of an NIH-funded Program Project, Petasis and dental biologist Thomas Van Dyke of Boston University then joined Serhan and his team at Brigham and Women’s Hospital and Harvard Medical School to study the role of lipoxins in periodontal disease.

In December 2003, this group published a report showing lipoxin analogs helped protect gums and teeth in an animal model of periodontitis. Their findings suggest that lipoxin analogs may prove helpful as a therapy for gum disease, the primary cause of adult tooth loss.

In the April 2004 issue of Nature Immunology, Petasis and a team led by physician-scientist Christopher L. Karp of Cincinnati Children’s Hospital found that cystic fibrosis patients produce markedly lower levels of natural lipoxins than healthy people.

The findings are the strongest evidence to date that uncontrolled inflammation, – and not bacterial infection – initiates the destructive cycle in the lungs that eventually proves fatal for most sufferers of this genetic disease.

Unraveling the whole story of inflammation – a tale both complex and redundant – will take time, said Petasis.

But some benefits from his research may arrive sooner: If the results of animal studies are borne out in future human trials, Petasis’ pro-healing compounds may offer doctors a potent and unique new tool in the anti-inflammatory arsenal.

“I tend to follow up with what happens with the molecules I create,” Petasis said. “You care about them as if they were your offspring. If a molecule you create proves useful, you can have an enormous positive impact.”


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "Scientists View 'Dark Side' Of The Body." ScienceDaily. ScienceDaily, 3 September 2004. <www.sciencedaily.com/releases/2004/09/040903093522.htm>.
University Of Southern California. (2004, September 3). Scientists View 'Dark Side' Of The Body. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2004/09/040903093522.htm
University Of Southern California. "Scientists View 'Dark Side' Of The Body." ScienceDaily. www.sciencedaily.com/releases/2004/09/040903093522.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins